NeuroVive Announces Publication of Phase I Clinical Trial of CicloMulsion® in ... Sacramento Bee The paper highlights that the intravenous cyclosporine formulation CicloMulsion® demonstrates bioequivalence and improved tolerability when compared with Sandimmune® Injection. The mitochondrial medicine company NeuroVive Pharmaceutical today ... |
